National Child Development Study

https://neurodegenerationresearch.eu/survey/national-child-development-study/

Title of cohort

National Child Development Study

Acronym for cohort

NCDS

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Alissa

Name of Principal Investigator - Last name

Goodman

Address of institution -Institution

UCL Institute of Education

Address of institution - Street address

UCL Institute of Education

Address of institution - City

London

Address of institution - Postcode

WC1H 0AL

Country

United Kingdom

Website

www.cls.ioe.ac.uk/ncds

Contact email

alissa.goodman@ucl.ac.uk

Funding source

Core funding from ESRC

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Neurodegenerative disease in general

Q1b. When are studies on the above condition(s) expected to become possible?

Already possible

Q2a. In a single sentence what is the stated aim of the cohort?

NCDS follows 17,000 people born in Great Britain in one week in 1958 and collects information on physical and educational development, economic circumstances, employment, family life, health, wellbeing and attitudes

Q2b. What distinguishes this cohort from other population cohorts?

NCDS is unparalleled internationally as an ongoing birth cohort of those born in the 1950s.

Q3a. i) Number of publications that involve use of your cohort to date

2631

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

NORTH, T.L, PALMER, T.M, LEWIS, S.J, COOPER, R, POWER, C, PATTIE, A, STARR, J.M, DEARY, I.J, MARTIN, R.M, AIHIE SAYER, A, KUMARI, M, COOPER, C, KIVIMAKI, M, KUH, D, BEN-SHLOMO, Y and DAY, I.N. (2015) Effect of smoking on physical and cognitive capability in later life: a multicohort study using observational and genetic approaches . BMJ Open, 5(12), e008393. | GEOFFROY, M-C, HERTZMAN, C, LI, L and POWER, C. (2012) Morning salivary cortisol and cognitive function in mid-life: evidence from a population-based birth cohort. Psychological Medicine, 42(8), 1763-1773. |DREGAN, A. and GULLIFORD, M. C. (2012) Is Illicit Drug Use Harmful to Cognitive Functioning in the Midadult Years? A Cohort-based Investigation. American Journal of Epidemiology, 175(3), 218-227

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

http://www.cls.ioe.ac.uk/Bibliography.aspx?sitesectionid=647&sitesectiontitle=Bibliography

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

Birth

Q4a. Study criteria: what is the age range of participants at recruitment? To:

Until death

Q4b. Study criteria: what are the inclusion criteria?

The NCDS original target sample was all births in England, Scotland and Wales in one week of March 1958. In addition, in advance of the age 7, age 11 and age 16 follow-ups the sample was augmented with immigrants born within the relevant week.

Q4c. Study criteria: what are the exclusion criteria?

N/A

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

More than 15,000 participants

Q6a. Please describe what measures are used to characterise participants

Information from childhood sweeps: Birth circumstances, birth weight, breastfeeding, general health, child development, specific conditions, disabilities/ special needs, hospital admissions, immunisation, medication, accidents, menstruation, eating problems, exercise, smoking, drinking, behavioural problems, emotional problems, sleeping problems, medical assessments (height, weight, audiometry, speech, co-ordination, vision, pubertal development), cognitive assessments, parental health, parental smoking.| Information from adult sweeps: General health, specific conditions, disability/limitations, menopause, weight, accidents, mental health, well-being, sleep, smoking, alcohol, drug use, diet, exercise, cognition.| Information from the biomedical survey (Age 44): Near, distance and stereo vision; hearing; lung function; blood pressure and pulse, height and weight; and waist and hip circumference. Samples of blood were taken from which DNA was extracted and immortalised cell cultures created (where consent was provided), from which the cohort has been extensively genotyped. Blood samples also used to measure lipids, clotting factors, inflammatory markers, total specific serum IgE. Saliva was collected to measure levels of cortisol.

Q6b. Are there additional measures for participants with a clinical disorder?
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If yes please specify
Q7. What is the study design (select all that apply)?

Prospective cohort| Longitudinal

Q8. Are your cases matched by

Age

Q9a. Does your study include a specialised subset of control participants?

No

Q9b. If your study includes a specialised subset of control participants please describe
Q10a. i) Please enter the data collection start date

01/03/1958

Q10a. ii) Please enter the data collection end date

N/A

Q10a. iii) Is data collection for this study

At the planning stage | Data collection ongoing| Data collection ongoing| Data collection ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?
Q11. Is data collected

Only through the study

Other please specify here

Also through links to medical records and other records

Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

Yes (participants given permission to be re-contacted via PIs)

Q13a. Please give information on the format and availability of data stored in a database (1)

Data summarised in database

% available

95

Q13a. Please give information on the format and availability of data stored in a database (2)

No

% available

Q13a. Please give information on the format and availability of data stored in a database (3)

No

% available
Q13a. Please give information on the format and availability of data stored in a database (4)

No

% available
Other (please specify)
% available
Q13b. Please give information on the format and availability of data held as individual records (1)

Data is held as individual records

% available

95

Q13b. Please give information on the format and availability of data held as individual records (2)

No

% available
Q13b. Please give information on the format and availability of data held as individual records (3)

No

% available
Q13b. Please give information on the format and availability of data held as individual records (4)

No

% available
Please specify language used

English

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource| Apply to PI or co-ordinator at resource| National access| International access| Resource has own ethics approval so usually no need for separate external ethics approval

Q15. What data sharing policy is specified as a condition of use?

Data to be made publicly available immediately

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below:

Living donors: blood| Living donors: DNA| Living donors: blood derivatives

Q16b. ii) In what form are tissues/samples/DNA supplied?

Primary Samples: Stabilised samples (frozen or fixed)| Secondary samples:(derivatives of primary samples)| Secondary samples: plasma| Secondary samples: DNA| Secondary samples: cell lines derived from primary samples

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

No

Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Number of Patients
% of total cohort

Types:
Population Cohorts

Member States:
United Kingdom

Diseases:
Neurodegenerative disease in general

Years:
2016

Database Categories:
N/A

Database Tags:
N/A